Moderna and Merck shares surge after melanoma vaccine success
A personalized vaccine developed by Moderna Inc. and Merck & Co.
Inc. helped reduce the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology .
Read More
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.
